Difficulty: Medium
Average Score: 79%
Practice
Indicate the beta receptor antagonist, which is used in the management of chronic heart failure:
Correct answer
B
Rationale
In the context of nursing pharmacology, understanding the use of beta receptor antagonists in the management of chronic heart failure is crucial for safe and effective patient care. The correct answer to the question is B) Metoprolol.
Metoprolol is a selective beta-1 receptor antagonist, making it a preferred choice in chronic heart failure. By blocking beta-1 receptors in the heart, metoprolol reduces the heart rate and contractility, thus decreasing the workload on the heart and improving its efficiency in pumping blood. This helps in managing the symptoms of heart failure and improving overall cardiac function.
Now, let's analyze why the other options are incorrect:
A) Propranolol: While propranolol is a non-selective beta blocker, meaning it blocks both beta-1 and beta-2 receptors, it is not the ideal choice for chronic heart failure due to its non-selectivity and potential to cause bronchoconstriction in patients with respiratory issues.
C) Pindolol: Pindolol is a non-selective beta blocker with intrinsic sympathomimetic activity. It is not commonly used in chronic heart failure management due to its unique pharmacological profile.
D) Sotalol: Sotalol is a beta blocker with class III antiarrhythmic properties. While it can be used in certain arrhythmias, it is not a first-line agent for chronic heart failure.
Educationally, this question helps students reinforce their understanding of beta blockers and their specific uses in different clinical conditions. It also emphasizes the importance of selecting the right medication based on its pharmacological properties and the patient's condition to achieve optimal therapeutic outcomes.
Metoprolol is a selective beta-1 receptor antagonist, making it a preferred choice in chronic heart failure. By blocking beta-1 receptors in the heart, metoprolol reduces the heart rate and contractility, thus decreasing the workload on the heart and improving its efficiency in pumping blood. This helps in managing the symptoms of heart failure and improving overall cardiac function.
Now, let's analyze why the other options are incorrect:
A) Propranolol: While propranolol is a non-selective beta blocker, meaning it blocks both beta-1 and beta-2 receptors, it is not the ideal choice for chronic heart failure due to its non-selectivity and potential to cause bronchoconstriction in patients with respiratory issues.
C) Pindolol: Pindolol is a non-selective beta blocker with intrinsic sympathomimetic activity. It is not commonly used in chronic heart failure management due to its unique pharmacological profile.
D) Sotalol: Sotalol is a beta blocker with class III antiarrhythmic properties. While it can be used in certain arrhythmias, it is not a first-line agent for chronic heart failure.
Educationally, this question helps students reinforce their understanding of beta blockers and their specific uses in different clinical conditions. It also emphasizes the importance of selecting the right medication based on its pharmacological properties and the patient's condition to achieve optimal therapeutic outcomes.